The Relationship Between Sarcopenia (Muscle Loss) and Hormone Therapy in Patients with Early Breast Cancer

What Is Sarcopenia?
A reduction or loss of muscle mass is what is meant by sarcopenia, a term that first entered the medical literature in the late 1980s and became a focus of research. In other words, sarcopenia is a decline in lean body mass or muscle mass occurring throughout life. Cancer patients may experience sarcopenia before diagnosis, during treatment, or afterward, and this can also occur in patients with breast cancer.
Sarcopenia in Patients with Breast Cancer
Hormone receptors (HR) are positive in most breast cancer patients. Taking hormone therapy for 5-10 years after surgery as adjuvant (preventive) treatment in women with estrogen receptor- and/or progesterone receptor-positive breast cancer reduces the risk of recurrence and improves survival.
Hormone therapy’s common side effects include musculoskeletal pain (arthralgia), hot flashes, and fatigue; hormone therapies have also been associated with loss of bone density and cardiovascular events.
Experiencing treatment-related side effects can reduce quality of life and treatment adherence. Identifying patients at high risk of these side effects can provide an opportunity for interventions to relieve them.
Although findings are conflicting, the relationships between body composition and breast cancer are well documented. Obesity is associated with increased breast cancer risk, but appears to have a protective effect in premenopausal women and reduce their risk. However, among breast cancer patients, those who are obese have larger tumors, faster disease progression, and a tendency to resist hormonal treatment. Evaluating body composition separately by its components (muscle, fat, and water) in breast cancer patients has been a potentially more informative approach.
Sarcopenia has been associated with increased mortality risk and lower quality of life, as well as poor outcomes in cancer. It can be detected by several methods, including computed tomography (BT) scans and bioelectrical impedance spectroscopy (BIS). BIS and BT images estimate muscle mass, which is then divided by the square of the patient’s height in meters to obtain the skeletal muscle index (SMI). Patients with low SMI are characterized as sarcopenic.
The Relationship Between Hormonal Therapy and Sarcopenia
In patients with both early breast cancer and metastatic breast cancer, sarcopenia has been predicted to worsen survival and has been associated with low chemotherapy completion rates. However, its effect on hormone therapy tolerance has not been well studied to date. This retrospective study, based on analysis of past data, evaluates the relationship between sarcopenia and severe side effects of hormone therapy in women with early breast cancer.
Table 1: Characteristics of Patients Included in the Study
|
Number of patients |
482 |
|
Age at Diagnosis Median (min-max) <65 years >65 years |
61 (29-88) 292 190 |
|
Race: White |
432 |
|
Body mass index Underweight (< 18.5 kg/m 2 ) Normal (18.5 to < 25 kg/m 2 ) Overweight (25 to < 30 kg/m 2 ) Obese (> 30 kg/m 2 ) |
6 (1%) 134 (28%) 189 (39%) 153 (32%) |
|
Breast cancer stage Stage 1 Stage 2 Stage 3 |
308 (64%) 125 (26%) 49 (10%) |
|
Comorbidities ≥ 1
Hypertension Diabetes Severe heart failure Cirrhosis Chronic kidney disease stage III KOAH Hypothyroidism Previous breast cancer Previous cancer Severe osteoarthritis Rheumatoid arthritis Coronary artery disease Peripheral vascular disease Osteoporosis Stroke |
360 (74%)
232 (48%) 70 (15%) 9 (2%) 5 (1%) 31 (7%) 30 (6%) 80 (17%) 27 (6%) 28 (6%) 89 (18%) 13 (3%) 14 (3%) 5 (1%) 115 (24%) 9 (2%) |
|
Treatment type (patients may have received 2 or more) Ovarian ablation Aromatase inhibitor Tamoksifen |
23 (5%) 419 (87%) 103 (21%) |
|
Skeletal Muscle Index (SMI) Kg/m 2 Median (min-max) Sarcopenia < 6.75 |
7.14 (4.84–12.61) 169 (35%) |
|
Early treatment change or discontinuation |
61 (13%) |
|
Endocrine toxicity |
58 (12%) |
13% of participants changed or discontinued treatment because of side effects. Patients with sarcopenia stopped or changed their medication more often because of side effects than those without sarcopenia.
Side Effects of Hormone Therapy
Medical records were reviewed to assess hormone therapy toxicities. Common and severe side effects related to hormone therapy were assessed, including arthralgia, fatigue, hot flashes, nausea/vomiting, bone fracture, and cardiovascular events (acute coronary syndrome, stroke, myocardial infarction, and pulmonary embolism).
The Relationship Between Sarcopenia and Hormone Therapy Toxicity
- Overall, 12% of patients experienced hormone therapy-related toxicities (arthralgia 8%, bone fracture 0%, cardiovascular events 0.8%, fatigue 1%, hot flashes 3%, nausea/vomiting 0%).
- People with sarcopenia were more likely to experience hormone therapy-related side effects than those without it.
- 13% of participants were observed to change or discontinue treatment because of side effects.
- Patients with sarcopenia stopped or changed their medication more frequently because of side effects than those without sarcopenia.
Conclusion and Commentary
Current guidelines recommend continuing adjuvant hormone therapy for 5 to 10 years. However, prolonged treatment combined with common side effects can make adherence difficult. Approximately 50% of patients reported not taking these drugs as often as prescribed, and approximately 20% stopped endocrine treatment during the first year because of side effects. Sarcopenia was identified as an important risk factor for hormone therapy toxicity and intolerance.
The reasons for reduced hormone therapy tolerance in patients with sarcopenia are their greater frailty and metabolic dysfunction. Patients with sarcopenia have been found to have higher levels of proinflammatory factors, such as fibrinogen, TNF-alfa, IL-6, and C-reactive protein, which can affect drug metabolism, lead to further sarcopenia, and disrupt cancer treatment because of side effects.
A recent study has shown that exercise may improve or reverse sarcopenia among cancer survivors (see Exercise is a cancer drug!). Physical exercise is often recommended to reduce arthralgia and other side effects of endocrine therapy. Exercise has been shown to reduce sarcopenia and improve bone density and quality of life in patients receiving hormone therapy. It would be interesting to investigate whether targeting patients with sarcopenia for a supervised exercise program could reduce hormone therapy toxicity and improve adherence.
*
Below, you can see our infographic poster to better understand breast cancer types and hormone-positive breast cancer:

Sources
2. M. Alexander Otto. Sarcopenia Nearly Doubles Risk Women Will Quit Endocrine Therapy - Medscape - May 17, 2022.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.